| Host: |
Rabbit |
| Applications: |
IHC-P |
| Reactivity: |
Human |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit monoclonal antibody anti-PHOX2B is suitable for use in Immunohistochemistry research applications. |
| Clonality: |
Monoclonal |
| Clone ID: |
ZR292 |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
Tris-HCI buffer containing stabilizing protein (BSA) and <0.1% ProClin |
| Purification: |
Affinity purified |
| Dilution Range: |
1:100-200 |
| Storage Instruction: |
Store at 2‐8°C for up to 24 months. Predilute: Ready to use, no reconstitution necessary. Concentrate: Use dilution range and appropriate lab‐standardized diluent. Stability after dilution: 7 days at 24°C, 3 months at 2‐8°C, 6months at ‐20°C. |
| Gene Symbol: |
PHOX2B |
| Gene ID: |
8929 |
| Uniprot ID: |
PHX2B_HUMAN |
| Specificity: |
Positive Control: Neuroblastoma |
| Immunogen: |
Recombinant fragment of human PHOX2B protein |
| Tissue Specificity | Expressed in neuroblastoma, brain and adrenal gland. |
| Function | Involved in the development of several major noradrenergic neuron populations, including the locus coeruleus. Transcription factor which could determine a neurotransmitter phenotype in vertebrates. Enhances second-messenger-mediated activation of the dopamine beta-hydrolase and c-fos promoters, and of several enhancers including cAMP-response element and serum-response element. |
| Protein Name | Paired Mesoderm Homeobox Protein 2bNeuroblastoma PhoxNbphoxPhox2b Homeodomain ProteinPaired-Like Homeobox 2b |
| Cellular Localisation | Nucleus |
| Alternative Antibody Names | Anti-Paired Mesoderm Homeobox Protein 2b antibodyAnti-Neuroblastoma Phox antibodyAnti-Nbphox antibodyAnti-Phox2b Homeodomain Protein antibodyAnti-Paired-Like Homeobox 2b antibodyAnti-PHOX2B antibodyAnti-PMX2B antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
